GlassScriptPhysician profile
Charles Mark Braverman
NPI 1316928864
$197.57
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $19.42 · 2022: $20.83.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $40.68 | 2019-2020 | |
| Glaxosmithkline, LLC. | $36.53 | 2019-2022 | |
| Genentech USA, INC. | $22.06 | 2019 | |
| Kaleo, INC. | $19.22 | 2019 | |
| Shire North American Group INC | $19.12 | 2019 | |
| Tris Pharma INC | $18.81 | 2019 | |
| Merck Sharp & Dohme LLC | $15.11 | 2019 | |
| Adlon Therapeutics L.P. | $13.11 | 2019 | |
| Cranial Technologies, INC | $12.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Braverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.